It’s been a decade since the first checkpoint inhibitors were approved, but the problem of low response rates remains in many forms of cancer. Highlight Therapeutics SL, of Valencia, Spain, hopes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback